img

Global and United States Pharmaceutical Intermediate CDMO Market Report & Forecast 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global and United States Pharmaceutical Intermediate CDMO Market Report & Forecast 2024-2034

Market Analysis and InsightsGlobal and United States Pharmaceutical Intermediate CDMO Market
This report focuses on global and United States Pharmaceutical Intermediate CDMO market, also covers the segmentation data of other regions in regional level and county level.
The global Pharmaceutical Intermediate CDMO revenue was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2033 with a CAGR of % during the review period (2023-2033).
In United States the Pharmaceutical Intermediate CDMO revenue is expected to grow from US$ million in 2022 to US$ million by 2033, at a CAGR of % during the forecast period 2023-2033.
The global key players of Pharmaceutical Intermediate CDMO include Cambrex, WR Grace, Esteve Química, AGC Pharma Chemicals, Evonik, CordenPharma, Otsuka Chemical, Wavelength and KBI Biopharma, etc. The global five biggest players hold a share of % in 2022.
Global Pharmaceutical Intermediate CDMO Scope and Market Size
Pharmaceutical Intermediate CDMO market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global Pharmaceutical Intermediate CDMO market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2033.
For United States market, this report focuses on the Pharmaceutical Intermediate CDMO market size by players, by Type and by Application, for the period 2018-2033. The key players include the global and local players, which play important roles in United States.



By Company


Cambrex
WR Grace
Esteve Química
AGC Pharma Chemicals
Evonik
CordenPharma
Otsuka Chemical
Wavelength
KBI Biopharma
Chengda Pharmaceuticals
Apeloa Pharmaceutical
Xi'an Manareco New Materials
Shenzhen Sungening Bio-technology
Chengdu D-innovation Pharmaceutical
Huateng Pharma
Segment by Type
Small Molecule Cdmo
Macromolecular Cdmo

Segment by Application


Pharmaceutical Company
Biotechnology Company
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa

Chapter Introduction


Chapter 1Introduces Pharmaceutical Intermediate CDMO definition, global market size, United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Pharmaceutical Intermediate CDMO companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Pharmaceutical Intermediate CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by application and by country revenue for each segment.
Chapter 7EMEA by type, by application and by region, revenue for each segment.
Chapter 8China by type, by application revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pharmaceutical Intermediate CDMO revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions

Table of Content

1 Study Coverage
1.1 Pharmaceutical Intermediate CDMO Product Introduction
1.2 Global Pharmaceutical Intermediate CDMO Outlook 2018 VS 2022 VS 2033
1.2.1 Global Pharmaceutical Intermediate CDMO Market Size for the Year 2018-2033
1.2.2 United States Pharmaceutical Intermediate CDMO Market Size for the Year 2018-2033
1.3 Pharmaceutical Intermediate CDMO Market Size, United States VS Global, 2018 VS 2022 VS 2033
1.3.1 The Market Share of United States Pharmaceutical Intermediate CDMO in Global, 2018 VS 2022 VS 2033
1.3.2 The Growth Rate of Pharmaceutical Intermediate CDMO Market Size, United States VS Global, 2018 VS 2022 VS 2033
1.4 Pharmaceutical Intermediate CDMO Market Dynamics
1.4.1 Pharmaceutical Intermediate CDMO Industry Trends
1.4.2 Pharmaceutical Intermediate CDMO Market Drivers
1.4.3 Pharmaceutical Intermediate CDMO Market Challenges
1.4.4 Pharmaceutical Intermediate CDMO Market Restraints
1.5 Assumptions and Limitations
1.6 Study Objectives
1.7 Years Considered
2 Pharmaceutical Intermediate CDMO by Type
2.1 Pharmaceutical Intermediate CDMO Market Segment by Type
2.1.1 Small Molecule Cdmo
2.1.2 Macromolecular Cdmo
2.2 Global Pharmaceutical Intermediate CDMO Market Size by Type (2018, 2022 & 2033)
2.3 Global Pharmaceutical Intermediate CDMO Market Size by Type (2018-2033)
2.4 United States Pharmaceutical Intermediate CDMO Market Size by Type (2018, 2022 & 2033)
2.5 United States Pharmaceutical Intermediate CDMO Market Size by Type (2018-2033)
3 Pharmaceutical Intermediate CDMO by Application
3.1 Pharmaceutical Intermediate CDMO Market Segment by Application
3.1.1 Pharmaceutical Company
3.1.2 Biotechnology Company
3.1.3 Others
3.2 Global Pharmaceutical Intermediate CDMO Market Size by Application (2018, 2022 & 2033)
3.3 Global Pharmaceutical Intermediate CDMO Market Size by Application (2018-2033)
3.4 United States Pharmaceutical Intermediate CDMO Market Size by Application (2018, 2022 & 2033)
3.5 United States Pharmaceutical Intermediate CDMO Market Size by Application (2018-2033)
4 Global Pharmaceutical Intermediate CDMO Competitor Landscape by Company
4.1 Global Pharmaceutical Intermediate CDMO Market Size by Company
4.1.1 Global Key Companies of Pharmaceutical Intermediate CDMO, Ranked by Revenue (2022)
4.1.2 Global Pharmaceutical Intermediate CDMO Revenue by Player (2018-2023)
4.2 Global Pharmaceutical Intermediate CDMO Concentration Ratio (CR)
4.2.1 Pharmaceutical Intermediate CDMO Market Concentration Ratio (CR) (2018-2023)
4.2.2 Global Top 5 and Top 10 Largest Companies of Pharmaceutical Intermediate CDMO in 2022
4.2.3 Global Pharmaceutical Intermediate CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Key Players of Pharmaceutical Intermediate CDMO Head office and Area Served
4.4 Global Key Players of Pharmaceutical Intermediate CDMO, Product and Application
4.5 Global Key Players of Pharmaceutical Intermediate CDMO, Date of Enter into This Industry
4.6 Companies Mergers & Acquisitions, Expansion Plans
4.7 United States Pharmaceutical Intermediate CDMO Market Size by Company
4.7.1 Key Players of Pharmaceutical Intermediate CDMO in United States, Ranked by Revenue (2022)
4.7.2 United States Pharmaceutical Intermediate CDMO Revenue by Players (2021, 2022 & 2023)
5 Global Pharmaceutical Intermediate CDMO Market Size by Region
5.1 Global Pharmaceutical Intermediate CDMO Market Size by Region: 2018 VS 2022 VS 2033
5.2 Global Pharmaceutical Intermediate CDMO Market Size by Region (2018-2033)
5.2.1 Global Pharmaceutical Intermediate CDMO Market Size by Region: 2018-2023
5.2.2 Global Pharmaceutical Intermediate CDMO Market Size by Region (2024-2033)
6 Americas
6.1 Americas Pharmaceutical Intermediate CDMO Market Size YoY Growth 2018-2033
6.2 Americas Pharmaceutical Intermediate CDMO Market Size by Type
6.2.1 Americas Pharmaceutical Intermediate CDMO Market Size by Type (2018-2023)
6.2.2 Americas Pharmaceutical Intermediate CDMO Market Size by Type (2024-2033)
6.2.3 Americas Pharmaceutical Intermediate CDMO Market Share by Type (2018-2033)
6.3 Americas Pharmaceutical Intermediate CDMO Market Size by Application
6.3.1 Americas Pharmaceutical Intermediate CDMO Market Size by Application (2018-2023)
6.3.2 Americas Pharmaceutical Intermediate CDMO Market Size by Application (2024-2033)
6.3.3 Americas Pharmaceutical Intermediate CDMO Market Share by Application (2018-2033)
6.4 Americas Pharmaceutical Intermediate CDMO Market Facts & Figures by Country (2018, 2022 & 2033)
6.4.1 United States
6.4.2 Canada
6.4.3 Mexico
6.4.4 Brazil
7 EMEA
7.1 EMEA Pharmaceutical Intermediate CDMO Market Size YoY Growth 2018-2033
7.2 EMEA Pharmaceutical Intermediate CDMO Market Size by Type
7.2.1 EMEA Pharmaceutical Intermediate CDMO Market Size by Type (2018-2023)
7.2.2 EMEA Pharmaceutical Intermediate CDMO Market Size by Type (2024-2033)
7.2.3 EMEA Pharmaceutical Intermediate CDMO Market Share by Type (2018-2033)
7.3 EMEA Pharmaceutical Intermediate CDMO Market Size by Application
7.3.1 EMEA Pharmaceutical Intermediate CDMO Market Size by Application (2018-2023)
7.3.2 EMEA Pharmaceutical Intermediate CDMO Market Size by Application (2024-2033)
7.3.3 EMEA Pharmaceutical Intermediate CDMO Market Share by Application (2018-2033)
7.4 EMEA Pharmaceutical Intermediate CDMO Market Facts & Figures by Country (2018, 2022 & 2033)
7.4.1 Europe
7.4.2 Middle East
7.4.3 Africa
8 China
8.1 China Pharmaceutical Intermediate CDMO Market Size YoY Growth 2018-2033
8.2 China Pharmaceutical Intermediate CDMO Market Size by Type
8.2.1 China Pharmaceutical Intermediate CDMO Market Size by Type (2018-2023)
8.2.2 China Pharmaceutical Intermediate CDMO Market Size by Type (2024-2033)
8.2.3 China Pharmaceutical Intermediate CDMO Market Share by Type (2018-2033)
8.3 China Pharmaceutical Intermediate CDMO Market Size by Application
8.3.1 China Pharmaceutical Intermediate CDMO Market Size by Application (2018-2023)
8.3.2 China Pharmaceutical Intermediate CDMO Market Size by Application (2024-2033)
8.3.3 China Pharmaceutical Intermediate CDMO Market Share by Application (2018-2033)
9 APAC (excluding China)
9.1 APAC Pharmaceutical Intermediate CDMO Market Size YoY Growth 2018-2033
9.2 APAC Pharmaceutical Intermediate CDMO Market Size by Type
9.2.1 APAC Pharmaceutical Intermediate CDMO Market Size by Type (2018-2023)
9.2.2 APAC Pharmaceutical Intermediate CDMO Market Size by Type (2024-2033)
9.2.3 APAC Pharmaceutical Intermediate CDMO Market Share by Type (2018-2033)
9.3 APAC Pharmaceutical Intermediate CDMO Market Size by Application
9.3.1 APAC Pharmaceutical Intermediate CDMO Market Size by Application (2018-2023)
9.3.2 APAC Pharmaceutical Intermediate CDMO Market Size by Application (2024-2033)
9.3.3 APAC Pharmaceutical Intermediate CDMO Market Share by Application (2018-2033)
9.4 APAC Pharmaceutical Intermediate CDMO Market Facts & Figures by Country (2018, 2022 & 2033)
9.4.1 Japan
9.4.2 South Korea
9.4.3 China Taiwan
9.4.4 Southeast Asia
9.4.5 India
10 Key Players Profiles
10.1 Cambrex
10.1.1 Cambrex Company Details
10.1.2 Cambrex Business Overview
10.1.3 Cambrex Pharmaceutical Intermediate CDMO Introduction
10.1.4 Cambrex Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
10.1.5 Cambrex Recent Development
10.2 WR Grace
10.2.1 WR Grace Company Details
10.2.2 WR Grace Business Overview
10.2.3 WR Grace Pharmaceutical Intermediate CDMO Introduction
10.2.4 WR Grace Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
10.2.5 WR Grace Recent Development
10.3 Esteve Química
10.3.1 Esteve Química Company Details
10.3.2 Esteve Química Business Overview
10.3.3 Esteve Química Pharmaceutical Intermediate CDMO Introduction
10.3.4 Esteve Química Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
10.3.5 Esteve Química Recent Development
10.4 AGC Pharma Chemicals
10.4.1 AGC Pharma Chemicals Company Details
10.4.2 AGC Pharma Chemicals Business Overview
10.4.3 AGC Pharma Chemicals Pharmaceutical Intermediate CDMO Introduction
10.4.4 AGC Pharma Chemicals Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
10.4.5 AGC Pharma Chemicals Recent Development
10.5 Evonik
10.5.1 Evonik Company Details
10.5.2 Evonik Business Overview
10.5.3 Evonik Pharmaceutical Intermediate CDMO Introduction
10.5.4 Evonik Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
10.5.5 Evonik Recent Development
10.6 CordenPharma
10.6.1 CordenPharma Company Details
10.6.2 CordenPharma Business Overview
10.6.3 CordenPharma Pharmaceutical Intermediate CDMO Introduction
10.6.4 CordenPharma Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
10.6.5 CordenPharma Recent Development
10.7 Otsuka Chemical
10.7.1 Otsuka Chemical Company Details
10.7.2 Otsuka Chemical Business Overview
10.7.3 Otsuka Chemical Pharmaceutical Intermediate CDMO Introduction
10.7.4 Otsuka Chemical Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
10.7.5 Otsuka Chemical Recent Development
10.8 Wavelength
10.8.1 Wavelength Company Details
10.8.2 Wavelength Business Overview
10.8.3 Wavelength Pharmaceutical Intermediate CDMO Introduction
10.8.4 Wavelength Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
10.8.5 Wavelength Recent Development
10.9 KBI Biopharma
10.9.1 KBI Biopharma Company Details
10.9.2 KBI Biopharma Business Overview
10.9.3 KBI Biopharma Pharmaceutical Intermediate CDMO Introduction
10.9.4 KBI Biopharma Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
10.9.5 KBI Biopharma Recent Development
10.10 Chengda Pharmaceuticals
10.10.1 Chengda Pharmaceuticals Company Details
10.10.2 Chengda Pharmaceuticals Business Overview
10.10.3 Chengda Pharmaceuticals Pharmaceutical Intermediate CDMO Introduction
10.10.4 Chengda Pharmaceuticals Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
10.10.5 Chengda Pharmaceuticals Recent Development
10.11 Apeloa Pharmaceutical
10.11.1 Apeloa Pharmaceutical Company Details
10.11.2 Apeloa Pharmaceutical Business Overview
10.11.3 Apeloa Pharmaceutical Pharmaceutical Intermediate CDMO Introduction
10.11.4 Apeloa Pharmaceutical Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
10.11.5 Apeloa Pharmaceutical Recent Development
10.12 Xi'an Manareco New Materials
10.12.1 Xi'an Manareco New Materials Company Details
10.12.2 Xi'an Manareco New Materials Business Overview
10.12.3 Xi'an Manareco New Materials Pharmaceutical Intermediate CDMO Introduction
10.12.4 Xi'an Manareco New Materials Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
10.12.5 Xi'an Manareco New Materials Recent Development
10.13 Shenzhen Sungening Bio-technology
10.13.1 Shenzhen Sungening Bio-technology Company Details
10.13.2 Shenzhen Sungening Bio-technology Business Overview
10.13.3 Shenzhen Sungening Bio-technology Pharmaceutical Intermediate CDMO Introduction
10.13.4 Shenzhen Sungening Bio-technology Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
10.13.5 Shenzhen Sungening Bio-technology Recent Development
10.14 Chengdu D-innovation Pharmaceutical
10.14.1 Chengdu D-innovation Pharmaceutical Company Details
10.14.2 Chengdu D-innovation Pharmaceutical Business Overview
10.14.3 Chengdu D-innovation Pharmaceutical Pharmaceutical Intermediate CDMO Introduction
10.14.4 Chengdu D-innovation Pharmaceutical Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
10.14.5 Chengdu D-innovation Pharmaceutical Recent Development
10.15 Huateng Pharma
10.15.1 Huateng Pharma Company Details
10.15.2 Huateng Pharma Business Overview
10.15.3 Huateng Pharma Pharmaceutical Intermediate CDMO Introduction
10.15.4 Huateng Pharma Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
10.15.5 Huateng Pharma Recent Development
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.2 Data Source
12.2 Disclaimer
12.3 Author Details

List of Figure

List of Tables
Table 1. Pharmaceutical Intermediate CDMO Market Size United States VS Global, CAGR (2018 VS 2022 VS 2033)
Table 2. Pharmaceutical Intermediate CDMO Market Trends
Table 3. Pharmaceutical Intermediate CDMO Market Drivers
Table 4. Pharmaceutical Intermediate CDMO Market Challenges
Table 5. Pharmaceutical Intermediate CDMO Market Restraints
Table 6. Global Pharmaceutical Intermediate CDMO Market Size by Type: 2018 VS 2022 VS 2033 (US$ Million)
Table 7. United States Pharmaceutical Intermediate CDMO Market Size by Type: 2018 VS 2022 VS 2033 (US$ Million)
Table 8. Global Pharmaceutical Intermediate CDMO Market Size by Application: 2018 VS 2022 VS 2033 (US$ Million)
Table 9. United States Pharmaceutical Intermediate CDMO Market Size by Application: 2018 VS 2022 VS 2033 (US$ Million)
Table 10. Global Key Companies of Pharmaceutical Intermediate CDMO, Ranked by Revenue (2022) & (US$ Million)
Table 11. Global Pharmaceutical Intermediate CDMO Revenue by Player, (US$ Million), 2018-2023
Table 12. Global Pharmaceutical Intermediate CDMO Revenue Share by Player, 2018-2023
Table 13. Global Pharmaceutical Intermediate CDMO Companies Market Concentration Ratio (CR5 and HHI)
Table 14. Global Pharmaceutical Intermediate CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmaceutical Intermediate CDMO as of 2022)
Table 15. Global Key Players of Pharmaceutical Intermediate CDMO, Headquarters and Area Served
Table 16. Global Key Players of Pharmaceutical Intermediate CDMO, Product and Application
Table 17. Global Key Players of Pharmaceutical Intermediate CDMO, Date of Enter into This Industry
Table 18. Companies Mergers & Acquisitions, Expansion Plans
Table 19. Key Players of Pharmaceutical Intermediate CDMO in United States, Ranked by Revenue (2022) & (US$ Million)
Table 20. United States Pharmaceutical Intermediate CDMO Revenue by Players, (US$ Million), 2021, 2022 & 2023
Table 21. United States Pharmaceutical Intermediate CDMO Revenue Share by Players, 2021, 2022 & 2023
Table 22. Global Pharmaceutical Intermediate CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 23. Global Pharmaceutical Intermediate CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 24. Global Pharmaceutical Intermediate CDMO Market Size Forecast by Region (2024-2033) & (US$ Million)
Table 25. Americas Pharmaceutical Intermediate CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 26. Americas Pharmaceutical Intermediate CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 27. Americas Pharmaceutical Intermediate CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 28. Americas Pharmaceutical Intermediate CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 29. Americas Pharmaceutical Intermediate CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 30. Americas Pharmaceutical Intermediate CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 31. Americas Pharmaceutical Intermediate CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 32. EMEA Pharmaceutical Intermediate CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 33. EMEA Pharmaceutical Intermediate CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 34. EMEA Pharmaceutical Intermediate CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 35. EMEA Pharmaceutical Intermediate CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 36. EMEA Pharmaceutical Intermediate CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 37. EMEA Pharmaceutical Intermediate CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 38. EMEA Pharmaceutical Intermediate CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 39. China Pharmaceutical Intermediate CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 40. China Pharmaceutical Intermediate CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 41. China Pharmaceutical Intermediate CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 42. China Pharmaceutical Intermediate CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 43. China Pharmaceutical Intermediate CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. APAC Pharmaceutical Intermediate CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 45. APAC Pharmaceutical Intermediate CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 46. APAC Pharmaceutical Intermediate CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 47. APAC Pharmaceutical Intermediate CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 48. APAC Pharmaceutical Intermediate CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 49. APAC Pharmaceutical Intermediate CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 50. APAC Pharmaceutical Intermediate CDMO Market Size by Region (2024-2033) & (US$ Million)
Table 51. Cambrex Company Details
Table 52. Cambrex Business Overview
Table 53. Cambrex Pharmaceutical Intermediate CDMO Product
Table 54. Cambrex Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023) & (US$ Million)
Table 55. Cambrex Recent Development
Table 56. WR Grace Company Details
Table 57. WR Grace Business Overview
Table 58. WR Grace Pharmaceutical Intermediate CDMO Product
Table 59. WR Grace Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023) & (US$ Million)
Table 60. WR Grace Recent Development
Table 61. Esteve Química Company Details
Table 62. Esteve Química Business Overview
Table 63. Esteve Química Pharmaceutical Intermediate CDMO Product
Table 64. Esteve Química Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023) & (US$ Million)
Table 65. Esteve Química Recent Development
Table 66. AGC Pharma Chemicals Company Details
Table 67. AGC Pharma Chemicals Business Overview
Table 68. AGC Pharma Chemicals Pharmaceutical Intermediate CDMO Product
Table 69. AGC Pharma Chemicals Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023) & (US$ Million)
Table 70. AGC Pharma Chemicals Recent Development
Table 71. Evonik Company Details
Table 72. Evonik Business Overview
Table 73. Evonik Pharmaceutical Intermediate CDMO Product
Table 74. Evonik Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023) & (US$ Million)
Table 75. Evonik Recent Development
Table 76. CordenPharma Company Details
Table 77. CordenPharma Business Overview
Table 78. CordenPharma Pharmaceutical Intermediate CDMO Product
Table 79. CordenPharma Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023) & (US$ Million)
Table 80. CordenPharma Recent Development
Table 81. Otsuka Chemical Company Details
Table 82. Otsuka Chemical Business Overview
Table 83. Otsuka Chemical Pharmaceutical Intermediate CDMO Product
Table 84. Otsuka Chemical Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023) & (US$ Million)
Table 85. Otsuka Chemical Recent Development
Table 86. Wavelength Company Details
Table 87. Wavelength Business Overview
Table 88. Wavelength Pharmaceutical Intermediate CDMO Product
Table 89. Wavelength Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023) & (US$ Million)
Table 90. Wavelength Recent Development
Table 91. KBI Biopharma Company Details
Table 92. KBI Biopharma Business Overview
Table 93. KBI Biopharma Pharmaceutical Intermediate CDMO Product
Table 94. KBI Biopharma Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023) & (US$ Million)
Table 95. KBI Biopharma Recent Development
Table 96. Chengda Pharmaceuticals Company Details
Table 97. Chengda Pharmaceuticals Business Overview
Table 98. Chengda Pharmaceuticals Pharmaceutical Intermediate CDMO Product
Table 99. Chengda Pharmaceuticals Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023) & (US$ Million)
Table 100. Chengda Pharmaceuticals Recent Development
Table 101. Apeloa Pharmaceutical Company Details
Table 102. Apeloa Pharmaceutical Business Overview
Table 103. Apeloa Pharmaceutical Pharmaceutical Intermediate CDMO Product
Table 104. Apeloa Pharmaceutical Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023) & (US$ Million)
Table 105. Apeloa Pharmaceutical Recent Development
Table 106. Xi'an Manareco New Materials Company Details
Table 107. Xi'an Manareco New Materials Business Overview
Table 108. Xi'an Manareco New Materials Pharmaceutical Intermediate CDMO Product
Table 109. Xi'an Manareco New Materials Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023) & (US$ Million)
Table 110. Xi'an Manareco New Materials Recent Development
Table 111. Shenzhen Sungening Bio-technology Company Details
Table 112. Shenzhen Sungening Bio-technology Business Overview
Table 113. Shenzhen Sungening Bio-technology Pharmaceutical Intermediate CDMO Product
Table 114. Shenzhen Sungening Bio-technology Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023) & (US$ Million)
Table 115. Shenzhen Sungening Bio-technology Recent Development
Table 116. Chengdu D-innovation Pharmaceutical Company Details
Table 117. Chengdu D-innovation Pharmaceutical Business Overview
Table 118. Chengdu D-innovation Pharmaceutical Pharmaceutical Intermediate CDMO Product
Table 119. Chengdu D-innovation Pharmaceutical Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023) & (US$ Million)
Table 120. Chengdu D-innovation Pharmaceutical Recent Development
Table 121. Huateng Pharma Company Details
Table 122. Huateng Pharma Business Overview
Table 123. Huateng Pharma Pharmaceutical Intermediate CDMO Product
Table 124. Huateng Pharma Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023) & (US$ Million)
Table 125. Huateng Pharma Recent Development
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. Pharmaceutical Intermediate CDMO Product Picture
Figure 2. Global Pharmaceutical Intermediate CDMO Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 3. Global Pharmaceutical Intermediate CDMO Market Size 2018-2033 (US$ Million)
Figure 4. United States Pharmaceutical Intermediate CDMO Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 5. United States Pharmaceutical Intermediate CDMO Market Size 2018-2033 (US$ Million)
Figure 6. United States Pharmaceutical Intermediate CDMO Market Share in Global 2018-2033
Figure 7. Pharmaceutical Intermediate CDMO Report Years Considered
Figure 8. Product Picture of Small Molecule Cdmo
Figure 9. Product Picture of Macromolecular Cdmo
Figure 10. Global Pharmaceutical Intermediate CDMO Market Share by Type in 2022 & 2033
Figure 11. Global Pharmaceutical Intermediate CDMO Market Size by Type (2018-2033) & (US$ Million)
Figure 12. Global Pharmaceutical Intermediate CDMO Market Share by Type (2018-2033)
Figure 13. United States Pharmaceutical Intermediate CDMO Market Share by Type in 2022 & 2033
Figure 14. United States Pharmaceutical Intermediate CDMO Market Size by Type (2018-2033) & (US$ Million)
Figure 15. United States Pharmaceutical Intermediate CDMO Market Share by Type (2018-2033)
Figure 16. Product Picture of Pharmaceutical Company
Figure 17. Product Picture of Biotechnology Company
Figure 18. Product Picture of Others
Figure 19. Global Pharmaceutical Intermediate CDMO Market Share by Application in 2022 & 2033
Figure 20. Global Pharmaceutical Intermediate CDMO Market Size by Application (2018-2033) & (US$ Million)
Figure 21. Global Pharmaceutical Intermediate CDMO Market Share by Application (2018-2033)
Figure 22. United States Pharmaceutical Intermediate CDMO Market Share by Application in 2022 & 2033
Figure 23. United States Pharmaceutical Intermediate CDMO Market Size by Application (2018-2033) & (US$ Million)
Figure 24. United States Pharmaceutical Intermediate CDMO Market Share by Application (2018-2033)
Figure 25. The Top 5 and 10 Largest Companies of Pharmaceutical Intermediate CDMO in the World: Market Share by Pharmaceutical Intermediate CDMO Revenue in 2022
Figure 26. Global Pharmaceutical Intermediate CDMO Market Size Market Share by Region: 2018 VS 2022 VS 2033
Figure 27. Global Pharmaceutical Intermediate CDMO Market Share by Region (2018-2033)
Figure 28. Americas Pharmaceutical Intermediate CDMO Market Size Growth Rate 2018-2033 (US$ Million)
Figure 29. Americas Pharmaceutical Intermediate CDMO Market Share by Type (2018-2033)
Figure 30. Americas Pharmaceutical Intermediate CDMO Market Share by Application (2018-2033)
Figure 31. United States Pharmaceutical Intermediate CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 32. Canada Pharmaceutical Intermediate CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 33. Mexico Pharmaceutical Intermediate CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 34. Brazil Pharmaceutical Intermediate CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 35. EMEA Pharmaceutical Intermediate CDMO Market Size Growth Rate 2018-2033 (US$ Million)
Figure 36. EMEA Pharmaceutical Intermediate CDMO Market Share by Type (2018-2033)
Figure 37. EMEA Pharmaceutical Intermediate CDMO Market Share by Application (2018-2033)
Figure 38. Europe Pharmaceutical Intermediate CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 39. Middle East Pharmaceutical Intermediate CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 40. Africa Pharmaceutical Intermediate CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 41. China Pharmaceutical Intermediate CDMO Market Size Growth Rate 2018-2033 (US$ Million)
Figure 42. China Pharmaceutical Intermediate CDMO Market Share by Type (2018-2033)
Figure 43. China Pharmaceutical Intermediate CDMO Market Share by Application (2018-2033)
Figure 44. APAC Pharmaceutical Intermediate CDMO Market Size Growth Rate 2018-2033 (US$ Million)
Figure 45. APAC Pharmaceutical Intermediate CDMO Market Share by Type (2018-2033)
Figure 46. APAC Pharmaceutical Intermediate CDMO Market Share by Application (2018-2033)
Figure 47. Japan Pharmaceutical Intermediate CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 48. South Korea Pharmaceutical Intermediate CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 49. China Taiwan Pharmaceutical Intermediate CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 50. Southeast Asia Pharmaceutical Intermediate CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 51. India Pharmaceutical Intermediate CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 52. Cambrex Revenue Growth Rate in Pharmaceutical Intermediate CDMO Business (2018-2023)
Figure 53. WR Grace Revenue Growth Rate in Pharmaceutical Intermediate CDMO Business (2018-2023)
Figure 54. Esteve Química Revenue Growth Rate in Pharmaceutical Intermediate CDMO Business (2018-2023)
Figure 55. AGC Pharma Chemicals Revenue Growth Rate in Pharmaceutical Intermediate CDMO Business (2018-2023)
Figure 56. Evonik Revenue Growth Rate in Pharmaceutical Intermediate CDMO Business (2018-2023)
Figure 57. CordenPharma Revenue Growth Rate in Pharmaceutical Intermediate CDMO Business (2018-2023)
Figure 58. Otsuka Chemical Revenue Growth Rate in Pharmaceutical Intermediate CDMO Business (2018-2023)
Figure 59. Wavelength Revenue Growth Rate in Pharmaceutical Intermediate CDMO Business (2018-2023)
Figure 60. KBI Biopharma Revenue Growth Rate in Pharmaceutical Intermediate CDMO Business (2018-2023)
Figure 61. Chengda Pharmaceuticals Revenue Growth Rate in Pharmaceutical Intermediate CDMO Business (2018-2023)
Figure 62. Apeloa Pharmaceutical Revenue Growth Rate in Pharmaceutical Intermediate CDMO Business (2018-2023)
Figure 63. Xi'an Manareco New Materials Revenue Growth Rate in Pharmaceutical Intermediate CDMO Business (2018-2023)
Figure 64. Shenzhen Sungening Bio-technology Revenue Growth Rate in Pharmaceutical Intermediate CDMO Business (2018-2023)
Figure 65. Chengdu D-innovation Pharmaceutical Revenue Growth Rate in Pharmaceutical Intermediate CDMO Business (2018-2023)
Figure 66. Huateng Pharma Revenue Growth Rate in Pharmaceutical Intermediate CDMO Business (2018-2023)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed